Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US) is GSK’s follow up to its respiratory blockbuster Advair/Seretide, but won’t come close to ...
Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta ... of the two drugs compared to their respective fixed-dose generic alternatives or open generic ...
The pharmacologic effects of beta 2-adrenoceptor agonist drugs, including vilanterol ... and treat if paradoxical bronchospasm occurs; use alternative therapy. Cardiovascular disease (esp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback